World Therapy: Vaginal Atrophy – Pipeline Review, H1 2012

• Publication date: March 2012

This report provides data on the therapeutic development for Vaginal Atrophy, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Vaginal Atrophy. 'Vaginal Atrophy - Pipeline Review, H1 2012' is built using data and information sourced from Global Industries Direct’s proprietary databases, Firms /University websites, SEC filings, inve...

This report provides data on the therapeutic development for Vaginal Atrophy, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Vaginal Atrophy. 'Vaginal Atrophy - Pipeline Review, H1 2012' is built using data and information sourced from Global Industries Direct’s proprietary databases, Firms /University websites, SEC filings, investor presentations and featured press releases from firm /university sites and market -specific third party sources, put together by Global Industries Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.



Scope of the Research


- A snapshot of the global therapeutic scenario for Vaginal Atrophy.
- A review of the Vaginal Atrophy products under development by industry players and universities/research institutes based on information derived from industry player and market -specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Vaginal Atrophy pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage new product development featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.



Reasons to buy


- Identify and understand important and diverse types of therapeutics under development for Vaginal Atrophy.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and take over s effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Vaginal Atrophy pipeline depth and focus of Vaginal Atrophy therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and grow business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Global Therapy Industry

Table of Contents

Data table of Contents
Data table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global March kets Direct Report Coverage 6
Vaginal Atrophy Overview 7
Therapeutics Development 8
An Overview of Pipeline Products for Vaginal Atrophy 8
Vaginal Atrophy Therapeutics under Development by Firms 10
Vaginal Atrophy Therapeutics under Investigation by Universities/Institutes 11
Late Stage Products 12
Comparative Analysis 12
Mid Clinical Stage Products 13
Comparative Analysis 13
Pre-Clinical Stage Products 14
Comparative Analysis 14
Vaginal Atrophy Therapeutics – Products under Development by Firms 15
Vaginal Atrophy Therapeutics – Products under Investigation by Universities/Institutes 16
Companies Involved in Vaginal Atrophy Therapeutics Development 17
Shionogi & Co., Ltd. 17
Arkopharma SA 18
Bayer AG 19
Bionovo, Inc. 20
Pear Tree Pharmaceuticals 21
Pantarhei Bioscience BV 22
Vaginal Atrophy – Therapeutics Assessment 23
Assessment by Monotherapy Products 23
Assessment by Route of Administration 24
Assessment by Molecule Type 26
Drug Profiles 28
Estetrol - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
Seala - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
Ophena - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Phyto Soya Vaginal Gel - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
clino-san - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
PT-200 - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
PT-101 - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Estradiol - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Estriol - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Vaginorm - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Vaginal Atrophy Therapeutics – Discontinued Products 42
Vaginal Atrophy Therapeutics - Dormant Products 43
Vaginal Atrophy – Product Development Milestones 44
Featured News & Press Releases 44
May 12, 2010: Ospemifene May Be Safe, Effective for Vulvovaginal Atrophy 44
March 02, 2010: Shionogi Enters Into Exclusive License Agreement With Quatrx Pharmaceuticals To March ket Ospemifene 44
September 10, 2009: Quatrx Announces Positive Results Of Second Pivotal Phase 3 Clinical Study For Ophena (Ospemifene Tablets) In Treatment Of Postmenopausal Vaginal Atrophy 45
July 29, 2009: Quatrx Announces Further Positive Phase 3 Results for ophena (ospemifene tablets) in postmenopausal vaginal atrophy 46
March 31, 2009: Quatrx Completes Erollment Of Ophena (ospemifene tablets) Final Pivotal Phase 3 Study In Women With Postmenopausal Vaginal Atrophy 47
September 26, 2008: Bionovo's VG101 Shows Greater Efficacy Than Estrogen In The Treatment Of Vaginal Dryness 48
September 24, 2008: Quatrx Pharmaceuticals Announces Additional Data From Phase 3 Study For Ophena (Ospemifene Tablets) Showing Improvements In Clinical Symptoms Of Vulvovaginal Atrophy 49
September 04, 2008: Quatrx Initiates Second Phase 3 Study Of Ophena (ospemifene tablets) In Women With Postmenopausal Vaginal Syndrome 50
June 16, 2008: Quatrx Pharmaceuticals Presents Results From Ophena (Ospemifene Tablets) Phase 3 Study Related To Treatment Of Symptoms Of Vulvovaginal Atrophy 51
May 21, 2008: Quatrx Pharmaceuticals Announces Presentation Of Further Data From Ophena (Ospemifene) Phase 3 Study For Treatment Of Symptoms Of VulvoVaginal Atrophy 52
Appendix 54
Methodology 54
Coverage 54
Secondary Research 54
Primary Research 54
Expert Panel Validation 54
Contact Us 55
Disclaimer 55

List of Tables

List of Tables
Number of Products Under Development for Vaginal Atrophy, H1 2012 8
Products under Development for Vaginal Atrophy – Comparative Analysis, H1 2012 9
Number of Products under Development by Firms, H1 2012 10
Number of Products under Investigation by Universities/Institutes, H1 2012 11
Comparative Analysis by Late Stage Development, H1 2012 12
Comparative Analysis by Mid Clinical Stage Development, H1 2012 13
Comparative Analysis by Pre-Clinical Stage Development, H1 2012 14
Products under Development by Firms, H1 2012 15
Products under Investigation by Universities/Institutes, H1 2012 16
Shionogi & Co., Ltd., H1 2012 17
Arkopharma SA, H1 2012 18
Bayer AG, H1 2012 19
Bionovo, Inc., H1 2012 20
Pear Tree Pharmaceuticals, H1 2012 21
Pantarhei Bioscience BV, H1 2012 22
Assessment by Monotherapy Products, H1 2012 23
Assessment by Stage and Route of Administration, H1 2012 25
Assessment by Stage and Molecule Type, H1 2012 27
Vaginal Atrophy Therapeutics – Discontinued Products 42
Vaginal Atrophy Therapeutics – Dormant Products 43

List of Figures

List of Figures
Number of Products under Development for Vaginal Atrophy, H1 2012 8
Products under Development for Vaginal Atrophy – Comparative Analysis, H1 2012 9
Products under Development by Firms, H1 2012 10
Products under Investigation by Universities/Institutes, H1 2012 11
Late Stage Products, H1 2012 12
Mid Clinical Stage Products, H1 2012 13
Pre-Clinical Stage Products, H1 2012 14
Assessment by Monotherapy Products, H1 2012 23
Assessment by Route of Administration, H1 2012 24
Assessment by Stage and Route of Administration, H1 2012 25
Assessment by Molecule Type, H1 2012 26
Assessment by Stage and Molecule Type, H1 2012 27